MOTS-c Compounding Pharmacy FDA and State Board Enforcement History

What Is MOTS-c and Why Does Its Regulatory Status Matter?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide first characterized by Lee et al. In 2015. It is not approved by the FDA for any human indication. Because it has no approved drug application, any compounding pharmacy selling injectable MOTS-c operates under rules that are strict, actively enforced, and frequently misunderstood by both prescribers and patients.

The 2015 Discovery and the Research Gap

Lee and colleagues showed in a 2015 Cell Metabolism paper (N=mice and human cell lines) that MOTS-c activates AMPK, improves insulin sensitivity, and reduces diet-induced obesity in rodent models [1]. That finding generated substantial interest in longevity and metabolic medicine communities. The problem is that no sponsor has completed a Phase II randomized controlled trial in humans, which means safety and efficacy data sufficient for FDA approval do not exist.

Without an approved new drug application (NDA), MOTS-c cannot legally be marketed as a drug. Compounding pharmacies that prepare it must therefore rely on the compounding exemptions in Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and those exemptions carry their own enforcement history [2].

The 503A vs. 503B Distinction

Section 503A covers traditional compounding pharmacies that prepare drugs for individual patients based on a valid prescription. Section 503B covers outsourcing facilities that may produce larger batches without patient-specific prescriptions but must register with the FDA and submit to regular inspections [2]. Injectable MOTS-c prepared as a sterile subcutaneous solution would need to meet 503A or 503B requirements, including full USP <797> compliance.

The FDA Regulatory Framework Governing Compounded Peptides

The FDA does not regulate compounding pharmacies the same way it regulates drug manufacturers, but it does have broad authority to act when compounded products are unsafe, adulterated, or marketed without legal basis. Several regulatory pillars apply directly to MOTS-c preparations.

USP <797>: The Sterile Compounding Standard

USP <797> sets minimum standards for beyond-use dating, environmental monitoring, personnel training, and sterility testing for all sterile compounded preparations [3]. A revised version of USP <797> took effect November 1, 2023, tightening requirements around:

• Category 1 vs. Category 2 compounded sterile preparations based on contamination risk
• Mandatory sterility testing for Category 2 preparations with longer beyond-use dates
• Stricter environmental monitoring frequency for cleanroom ISO classifications

Any pharmacy compounding injectable MOTS-c that does not operate under the 2023 revised USP <797> is operating below current minimum standards.

USP <795> and Non-Sterile Forms

Some suppliers sell MOTS-c as a lyophilized powder or oral capsule. Non-sterile preparations fall under USP <795>, which requires accurate formulation, appropriate beyond-use dating, and suitable packaging. The 2023 revision to USP <795> also took effect November 1, 2023, aligning its timeline with the sterile standard [3].

The DSCSA and Traceability

The Drug Supply Chain Security Act (DSCSA), fully phased in by November 2024, requires electronic tracing of prescription drug products through the supply chain [4]. While 503A compounders have limited DSCSA obligations, 503B outsourcing facilities must participate in the track-and-trace system. Buyers who cannot obtain a chain-of-custody record for their MOTS-c vials should treat that gap as a quality warning.

FDA Enforcement Actions Relevant to Peptide Compounding

The FDA has not issued a warning letter naming MOTS-c specifically as of early 2025, but it has issued a series of enforcement actions targeting compounded peptides and the pharmacies that supply them. These actions define the regulatory environment MOTS-c compounders inhabit.

The 2021-2024 Peptide Warning Letter Wave

Beginning in 2021, the FDA intensified scrutiny of pharmacies compounding BPC-157, TB-500 (Thymosin Beta-4), and other research peptides, citing them as unapproved new drugs and adulterated products under 21 U.S.C. 351 [5]. The FDA's position, stated consistently in those letters, is that a substance without an approved application or an active IND cannot be legally compounded for human use simply because a prescriber writes a script for it.

The FDA's Office of Pharmaceutical Quality issued a 2022 guidance document clarifying that bulk drug substances used in compounding must appear on an FDA-approved list (the "503A bulks list" or "503B bulks list") or have a USP monograph, or be the subject of an approved drug application [6]. MOTS-c appears on none of those lists.

FDA Warning Letters to 503B Outsourcing Facilities

The FDA publishes all warning letters at fda.gov. A review of 503B warning letters from 2020 to 2024 shows recurring violations including:

• Failure to conduct adequate sterility testing before product release
• Out-of-specification microbial environmental monitoring results
• Inadequate investigations of sterility failures
• Marketing products not on the 503B bulks list without lawful basis [5]

Any pharmacy currently compounding MOTS-c faces these same potential citations. The FDA can issue a warning letter, place an import alert, or seek an injunction against continued operations.

The Bulk Drug Substances List and MOTS-c's Absence

The 503A bulks list and 503B bulks list are the legal "on-ramps" for substances that lack their own NDA. MOTS-c has not been nominated or evaluated for either list as of January 2025 [6]. That absence means a pharmacy preparing MOTS-c for human use has no explicit statutory safe harbor. The FDA could act against such a pharmacy at any time.

The HealthRX Pharmacy Vetting Framework for unapproved peptides (developed internally based on FDA guidance, USP standards, and PCAB audit criteria) scores pharmacies across five domains: licensure verification, COA documentation, sterility testing records, prescriber relationship model, and regulatory history. A pharmacy must clear all five domains before HealthRX clinicians consider it for patient referral.

State Board of Pharmacy Enforcement

State boards of pharmacy license compounding pharmacies within their states and have independent authority to inspect, cite, and discipline facilities. Their standards often mirror, and sometimes exceed, FDA requirements.

How State Boards Operate

Each state board enforces the state's pharmacy practice act. Most states have adopted NABP (National Association of Boards of Pharmacy) model rules that track USP <797> and USP <795>. When the FDA refers a complaint or shares inspection findings, state boards frequently open parallel investigations [7].

NABP's Not-Recommended Site List

The NABP maintains a list of "not recommended" online pharmacies based on compliance concerns. Buying MOTS-c from a site that appears on this list means buying from an operation that multiple oversight bodies have flagged. The NABP list is searchable at nabp.pharmacy and updated regularly [7].

PCAB Accreditation as a Positive Signal

The Pharmacy Compounding Accreditation Board (PCAB), administered by NABP, provides voluntary accreditation to compounding pharmacies that pass third-party audits against USP standards. PCAB-accredited facilities are not immune to violations, but the accreditation signals a demonstrated commitment to quality systems. As of 2025, fewer than 200 U.S. Pharmacies hold PCAB accreditation, representing a small fraction of all compounders [7].

Quality Testing Standards for Compounded MOTS-c

Understanding what a legitimate certificate of analysis (COA) should contain is the most practical skill a buyer or prescriber can develop. Three tests are non-negotiable for injectable peptides.

HPLC Purity Testing

High-performance liquid chromatography (HPLC) separates a peptide sample into its components and quantifies the target compound as a percentage of total peak area. A COA showing ≥98% purity by HPLC is the floor for clinical-grade material. Anything below 95% should be rejected. The COA should name the instrument, the column, the mobile phase, and the run date [8].

Sterility Testing

USP <71> sterility testing detects viable microorganisms in the final product. Category 2 compounded sterile preparations under revised USP <797> require this test before release when beyond-use dating exceeds 14 days at room temperature or 45 days refrigerated. A pharmacy that cannot provide a sterility test result for a batch of injectable MOTS-c is not meeting current standards [3].

Endotoxin (LAL) Testing

Bacterial endotoxins cause fever, sepsis, and death even when a preparation is technically sterile. The Limulus Amebocyte Lysate (LAL) test, specified in USP <85>, detects endotoxin to below 0.5 EU/mL in many parenteral preparations. The parenteral limit defined by FDA guidance is <5 EU/kg/hr for most routes [9]. A COA for injectable MOTS-c must include a passing LAL result with the actual EU/mL value, not just a "pass" notation.

Mass Spectrometry Confirmation

High-resolution mass spectrometry (HRMS) confirms molecular identity beyond what HPLC alone can verify. Some analytical labs providing COAs for peptides now include LC-MS/MS data confirming the correct molecular mass and fragmentation pattern. This is the current best practice for confirming that the 16-amino-acid sequence of MOTS-c is intact and unmodified [8].

Is MOTS-c Legal to Buy?

The legal answer depends on jurisdiction, intended use, and the source. Possession of a small quantity for personal use has not been the target of federal prosecution, but selling MOTS-c without a valid drug application or compounding exemption is a violation of federal law.

The "Research Use Only" Label

Many online suppliers sell MOTS-c vials labeled "for research use only, not for human use." This label does not create a legal exemption from FDA drug regulations if the supplier has reason to believe the buyer intends human use. The FDA has explicitly addressed this in import alert guidance, noting that "research use only" labeling does not immunize a product from drug adulteration or misbranding charges [5].

Prescription Requirement and Practitioner Liability

A licensed prescriber who writes a prescription for MOTS-c from a 503A pharmacy takes on regulatory exposure if the pharmacy is not compliant or if the substance is later determined to be unlawful to compound. The FDA's 2024 enforcement policy memoranda on unapproved peptides signal increasing willingness to address the prescriber side of non-compliant compounding chains [6].

Importation from Foreign Suppliers

Importing MOTS-c from China-based peptide manufacturers is subject to FDA import alert authority. Import Alert 66-41, which covers unapproved new drugs, gives FDA field offices authority to detain shipments without physical examination [5]. Packages detained under this alert are seized; the buyer receives no refund.

How to Choose a Pharmacy for MOTS-c: Practical Buyer Guidance

Given the enforcement environment above, buyers who work with a prescriber to obtain compounded MOTS-c should apply a structured vetting process.

Verify State Licensure

Every legitimate compounding pharmacy must hold an active license in the state where it operates and, for mail-order operations, non-resident pharmacy licenses in each state it ships to. License status is verifiable through each state board's public lookup tool.

Request the Full COA Package

A complete COA package for injectable MOTS-c should include:

• HPLC purity report (≥98%) with chromatogram
• Sterility test result (USP <71>, method and incubation period specified)
• Endotoxin test result (USP <85>, EU/mL value stated)
• Mass spectrometry confirmation of molecular identity
• Beyond-use date calculation with storage conditions
• Lot number traceability to raw material certificates

Refusing or being unable to supply this package is disqualifying.

Check FDA Warning Letter History

The FDA warning letter database at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters is searchable by company name and date [5]. Run the pharmacy's legal name before ordering.

Confirm PCAB Status or Third-Party Audit

Check NABP's PCAB accreditation directory. If the pharmacy is not PCAB-accredited, ask whether it undergoes annual third-party USP <797> compliance audits and request the most recent audit summary.

Assess the Prescriber Relationship Model

Legitimate 503A compounders require a valid patient-specific prescription from a licensed prescriber who has established a bona fide prescriber-patient relationship. A pharmacy that sells injectable peptides without a prescription, or that provides a "template prescription" for patients to self-sign, is violating federal law.

The Clinical Research Field and Why It Matters for Regulation

Understanding why regulators are cautious about MOTS-c requires looking at the available human data, which is thin.

Rodent and In Vitro Evidence

The foundational 2015 Lee et al. Paper in Cell Metabolism demonstrated that MOTS-c administration reduced adipose tissue accumulation and improved glucose tolerance in high-fat-diet mice [1]. A 2019 study in Nature Communications (N=rodents) showed MOTS-c improved exercise capacity and AMPK signaling in skeletal muscle [10]. These are mechanistically interesting findings. They are not evidence of human safety or efficacy at compounding doses.

Human Data: What Exists

A small pilot study published in 2021 examined circulating MOTS-c levels in older adults and found a correlation between lower MOTS-c plasma concentrations and reduced insulin sensitivity [1]. That is an observational association, not an interventional trial. No published Phase II randomized controlled trial of exogenous MOTS-c administration in humans existed as of January 2025. ClinicalTrials.gov lists exploratory registrations but no completed Phase II results [11].

The absence of human trial data is precisely why the FDA has no approved pathway for MOTS-c and why compounding pharmacies operating in this space carry heightened regulatory risk.

Endocrine Society Position on Peptides

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy does not mention MOTS-c, reflecting its pre-clinical status [12]. As the Society's guidelines note, "pharmacotherapy should be used as part of a comprehensive lifestyle program" and should involve only agents with established efficacy and safety profiles in humans [12].

Red Flags That Signal an Unsafe MOTS-c Source

Certain supplier behaviors predict poor quality or legal non-compliance.

No verifiable physical address or state pharmacy license number posted on the website is a strong warning. Pricing dramatically below market (high-purity 10 mg MOTS-c from a compliant 503A pharmacy typically costs $150-$300 per vial depending on batch size) suggests raw material sourcing that bypasses quality testing. A COA that lists only purity percentage without chromatogram data is not a real COA. Any claim that MOTS-c is "FDA-approved" or "FDA-cleared" is false and may indicate broader misrepresentation across the product line.

The FDA's MedWatch program accepts consumer and practitioner reports of adverse events from compounded products at fda.gov/safety/medwatch [9]. Filing a report when a compounded peptide causes harm creates the adverse event record that supports future regulatory action.